Safety of influenza vaccines

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 4, 2012, Pages 383-388

  Kelso, John M ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

egg allergy; influenza vaccine; safety; side effects

Indexed keywords

INFLUENZA VACCINE; OVALBUMIN; TRIPLE VACCINE;

ANAPHYLAXIS; ASTHMA; CAMPYLOBACTER JEJUNI; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EGG ALLERGY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MEDICAL HISTORY; PRIORITY JOURNAL; REVIEW; SKIN TEST;

AGE FACTORS; ASTHMA; DRUG TOXICITY; EGGS; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; HYPERSENSITIVITY; IMMUNIZATION; INFLUENZA VACCINES; MALE; TIME FACTORS; VACCINES, ATTENUATED;

EID: 84864223647     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328354395d     Document Type: Review

References (39)

1. Estimates of deaths associated with seasonal influenza: United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-1062.
2. Monto AS, Ohmit SE, Petrie JG, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-1267.
3. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:1-62.
4. Prevention and Control of Influenza with Vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1128-1132.
5. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998; 133:624-628. (Pubitemid 28521210)
6. Chung EY, Huang L, Schneider L. Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 2010; 125:e1024-e1030.
7. Gagnon R, Primeau MN, Des Roches A, et al. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J Allergy Clin Immunol 2010; 126:317-323.
8. Greenhawt MJ, Chernin AS, Howe L, et al. The safety of the H1N1 influenza A vaccine in egg allergic individuals. Ann Allergy Asthma Immunol 2010; 105:387-393.
9. Owens G, Macginnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011; 127:264-265.
10. Webb L, Petersen M, Boden S, et al. Single-dose influenza vaccination of patients with egg allergy in a multicenter study. J Allergy Clin Immunol 2011; 128:218-219.
11. Howe LE, Conlon AS, Greenhawt MJ, Sanders GM. Safe administration of seasonal influenza vaccine to children with egg allergy of all severities. Ann Allergy Asthma Immunol 2011; 106:446-447.
12. Kelso JM, Li JT, Nicklas RA, et al. Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103:S1-S14.
13. Waibel KH, Gomez R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J Allergy Clin Immunol 2010; 125:749-751; 51 e1.
14. Li JT, Rank MA, Squillace DL, Kita H. Ovalbumin content of influenza vaccines. J Allergy Clin Immunol 2010; 125:1412-1413.
15. McKinney KK, Webb L, Petersen M, et al. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011; 127:1629-1632.
16. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813-825.
17. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis 2010; 10:643-651.
18. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barre syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48-56.
19. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vaccine 2007; 25:5253-5255. (Pubitemid 46977531)
20. Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 2006; 12:29-33. (Pubitemid 43143531)
21. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979; 110:105-123. (Pubitemid 10209694)
22. Centers for Disease Control and P. Preliminary results: surveillance for Guillain-Barre syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. MMWR Morb Mortal Wkly Rep 2010; 59:657-661.
23. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality Washington, DC: The National Academies Press; 2011.
24. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1-62.
25. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001; 345:1529-1536.
26. Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23:138-144. (Pubitemid 38222786)
27. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005; 116:e397-e407. (Pubitemid 44339432)
28. Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860-869. (Pubitemid 44510577)
29. Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 2008; 27:444-452.
30. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493-504.
31. Nailescu C, Xu X, Zhou H, et al. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 2011; 26:459-467.
32. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17:434-438.
33. Goldschmidt I, Pfister ED, Becker M, et al. Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients. J Pediatr 2011; 158:329-333.
34. Mackay HJ, McGee J, Villa D, et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011; 50:212-216.
35. Fabio V, Daniele F, Monica de D, et al. Pancreas rejection after pandemic influenzavirus A(H1N1) vaccination or infection: a report of two cases. Transpl Int 2011; 24:e28-e29.
36. Madhi SA, Maskew M, Koen A, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-137.
37. Tennis P, Toback SL, Andrews E, et al. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 2011; 29:4947-4952.
38. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011; 60:1-64.
39. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. MMWR Morb Mortal Wkly Rep 2010; 59:989-992.